BACKGROUND/AIMS: The incidence of @entity86 differs between @entity1 with and those without congenital intrahepatic bile duct dilatation. The aim of this study was to evaluate comparatively the treatment results in these two @entity1 groups. METHODOLOGY: Forty-eight @entity1 were classified into those with (dilated type) and those without (nondilated type) intrahepatic bile duct dilatation. The surgical procedure used, clinical manifestation, and cell kinetics (proliferating cell nuclear antigen labeling index, PCNALI) of bile duct epithelium were examined with respect to the incidence and course of @entity86 . RESULTS: Nineteen @entity1 were classified as the dilated type, and the other 29 @entity1 were the nondilated type. In the dilated-type group, hepaticoduodenostomy was performed on five @entity1 , hepaticojejunostomy (Roux-en-Y method) on eight and jejunal interposition on six. Among the 29 nondilated-type @entity1 , hepaticoduodenostomy was performed on 19 @entity1 , hepaticojejunostomy (Roux-en-Y method) on seven, and jejunal interposition on three. Hepatectomy was performed in one dilated-type adult @entity1 with marked @entity99 . The incidence of @entity86 was 26.3% (5/19) in the dilated-type group and 6.9% (2/29) in the nondilated-type group. The clinical manifestation was generally mild in the nondilated-type @entity1 . However, among the adult dilated-type @entity1 , on whom jejunal interposition had been performed, there were two @entity1 who required additional surgery for the treatment of @entity255 that occurred postoperatively. The PCNALI in the bile duct epithelium was 13.9% for the dilated-type and 8.8% for the nondilated-type groups, respectively. CONCLUSIONS: Jejunal interposition for biliary reconstruction seems a contraindicated maneuver for adult dilated-type @entity1 , because of the possible development of @entity86 . The cellular proliferating activity in the bile duct epithelium of the @entity1 of both the dilated and nondilated type was significantly increased compared to that of a control group. Consequently, the extrahepatic bile duct might have to be removed in @entity1 with pancreaticobiliary maljunction regardless of the presence or absence of @entity384 .

Surgical treatment for XXXX , with or without intrahepatic bile duct dilatation.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity384 :: ('MESH:D002311', 'Disease') :: ['biliary dilatation'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative cholangitis'] @entity99 :: ('MESH:D056486', 'Disease') :: ['cholangiectasia in the left hepatic lobe'] @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']
@entity384 :: (MESH:D002311,Disease) :: ['congenital biliary dilatation']
